Salud Pública y Materno-Infantil
Departamento
![Foto de Salud Pública y Materno-Infantil](/img/noimage.png)
![Foto de University Medical Center Hamburg-Eppendorf](/img/noimage_org.png)
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaPublicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (15)
2024
-
Correction: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report (International Journal of Mental Health and Addiction, (2023), 10.1007/s11469-023-01213-9)
International Journal of Mental Health and Addiction
-
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study
Journal of Allergy and Clinical Immunology, Vol. 153, Núm. 1, pp. 275-286.e18
-
Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study
Clinical Infectious Diseases, Vol. 79, Núm. 1, pp. 215-222
2023
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727
-
Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report
International Journal of Mental Health and Addiction
2022
-
A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Journal of Clinical Immunology, Vol. 42, Núm. 3, pp. 500-511
2021
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
-
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study
Vaccine, Vol. 39, Núm. 20, pp. 2800-2809
2020
-
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations
Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 4, pp. 901-911
2017
-
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Journal of Pediatrics, Vol. 189, pp. 72-78.e3
-
Progressive deafness–dystonia due to SERAC1 mutations: A study of 67 cases
Annals of Neurology, Vol. 82, Núm. 6, pp. 1004-1015
2016
2006
-
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease
Brain, Vol. 129, Núm. 9, pp. 2278-2287
2003
-
Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research
Journal of Medical Virology, Vol. 69, Núm. 2, pp. 195-201
2001
-
Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus: European Paediatric Hepatitis C Virus Network
British Journal of Obstetrics and Gynaecology, Vol. 108, Núm. 4, pp. 371-377